12:00 AM
 | 
Oct 03, 2016
 |  BC Week In Review  |  Clinical News  |  Clinical Status

APG101: Phase I/II started

Canbridge began a Taiwanese Phase I/II trial to evaluate once-weekly 200 and 400 mg IV CAN-008 plus temozolomide in about 55 patients with newly diagnosed GBM. The trial comprises an open-label, dose-escalation Phase I portion and...

Read the full 157 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >